MA33973B1 - Méthodes de traitement du cancer à l'aide d'antagonistes de notch - Google Patents

Méthodes de traitement du cancer à l'aide d'antagonistes de notch

Info

Publication number
MA33973B1
MA33973B1 MA34797A MA34797A MA33973B1 MA 33973 B1 MA33973 B1 MA 33973B1 MA 34797 A MA34797 A MA 34797A MA 34797 A MA34797 A MA 34797A MA 33973 B1 MA33973 B1 MA 33973B1
Authority
MA
Morocco
Prior art keywords
ways
treat cancer
notch
notch antagonists
antagonists
Prior art date
Application number
MA34797A
Other languages
Arabic (ar)
English (en)
Inventor
Christian W Siebel
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA33973B1 publication Critical patent/MA33973B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La présente invention porte sur des méthodes pour le traitement du cancer en général, et de la leucémie en particulier, à l'aide d'antagonistes de Notch1 et de Notch3 séparément ou en combinaison. L'invention porte également sur des compositions et sur des méthodes pour le traitement et le diagnostic de cancers associés à Notch.
MA34797A 2009-09-30 2010-09-29 Méthodes de traitement du cancer à l'aide d'antagonistes de notch MA33973B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24729809P 2009-09-30 2009-09-30
PCT/US2010/050610 WO2011041336A2 (fr) 2009-09-30 2010-09-29 Méthodes de traitement du cancer à l'aide d'antagonistes de notch

Publications (1)

Publication Number Publication Date
MA33973B1 true MA33973B1 (fr) 2013-02-01

Family

ID=43127684

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34797A MA33973B1 (fr) 2009-09-30 2010-09-29 Méthodes de traitement du cancer à l'aide d'antagonistes de notch

Country Status (21)

Country Link
US (1) US9200071B2 (fr)
EP (1) EP2483311B1 (fr)
JP (3) JP6025563B2 (fr)
KR (1) KR101782180B1 (fr)
CN (1) CN102630229B (fr)
AU (1) AU2010300747A1 (fr)
BR (1) BR112012007252A2 (fr)
CA (1) CA2775880A1 (fr)
CL (1) CL2012000800A1 (fr)
CO (1) CO6531430A2 (fr)
CR (1) CR20120213A (fr)
EC (1) ECSP12011858A (fr)
ES (1) ES2580229T3 (fr)
HK (1) HK1170505A1 (fr)
IL (1) IL218662A0 (fr)
MA (1) MA33973B1 (fr)
MX (1) MX342250B (fr)
PE (1) PE20120998A1 (fr)
RU (1) RU2012117619A (fr)
WO (1) WO2011041336A2 (fr)
ZA (1) ZA201201984B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
EP2125887A4 (fr) 2007-01-24 2010-11-10 Oncomed Pharm Inc Compositions et procedes utilises pour le diagnostic et le traitement du cancer
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
PL2307459T3 (pl) 2008-07-08 2015-05-29 Oncomed Pharm Inc Czynniki wiążące receptor Notch1 i sposoby ich stosowania
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
RU2011151287A (ru) 2009-06-18 2013-07-27 Пфайзер Инк. АНТИ Notch-1 АНТИТЕЛА
RU2622083C2 (ru) 2010-12-15 2017-06-09 ВАЙЕТ ЭлЭлСи Антитела против notch1
AU2013343045A1 (en) * 2012-11-07 2015-05-21 Pfizer Inc. Anti-Notch3 antibodies and antibody-drug conjugates
ES2737649T3 (es) 2012-12-19 2020-01-15 Aveo Pharmaceuticals Inc Anticuerpos anti-Notch3
WO2014159239A2 (fr) * 2013-03-14 2014-10-02 Novartis Ag Anticorps dirigés contre notch 3
WO2014159242A1 (fr) * 2013-03-14 2014-10-02 Novartis Ag Mutants de notch 3 et leurs utilisations
WO2014151606A2 (fr) * 2013-03-15 2014-09-25 Oncomed Pharmaceuticals, Inc. Procédés de traitement du cancer du pancréas
KR20160104612A (ko) 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조성물
JP6571115B2 (ja) 2014-02-12 2019-09-04 ジェネンテック， インコーポレイテッド 抗ｊａｇｇｅｄ１抗体及び使用方法
KR20170029490A (ko) 2014-07-11 2017-03-15 제넨테크, 인크. 노치 경로 억제
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
WO2017190025A1 (fr) * 2016-04-29 2017-11-02 Aveo Pharmaceuticals, Inc. Anticorps anti-notch3

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2219361C (fr) 1995-04-27 2012-02-28 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2305027B1 (fr) 1996-12-03 2014-07-02 Amgen Fremont Inc. Mammifères trangèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus.
EP1034298B1 (fr) 1997-12-05 2011-11-02 The Scripps Research Institute Humanisation d'anticorps murins
EA200701211A1 (ru) 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
PE20081264A1 (es) 2006-10-19 2008-10-01 Genentech Inc Anticuerpos agonistas anti-notch3
CA2666179A1 (fr) 2006-10-19 2008-11-13 Genentech, Inc. Nouveaux anticorps anti-notch3 et leur utilisation dans la detection et le diagnostic d'une maladie
US7935791B2 (en) * 2006-12-18 2011-05-03 Genentech, Inc. Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
EP2125887A4 (fr) * 2007-01-24 2010-11-10 Oncomed Pharm Inc Compositions et procedes utilises pour le diagnostic et le traitement du cancer
US20100062012A1 (en) * 2007-03-05 2010-03-11 Ioannides Constantin G Negative Genetic Regulation of Cancer Cell Renewal in Synergy with Notch- or Numb-Specific Immunotherapy
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
PL2307459T3 (pl) * 2008-07-08 2015-05-29 Oncomed Pharm Inc Czynniki wiążące receptor Notch1 i sposoby ich stosowania
WO2010141249A2 (fr) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Génération, caractérisation et utilisations d'anticorps anti-notch3
RU2011151287A (ru) * 2009-06-18 2013-07-27 Пфайзер Инк. АНТИ Notch-1 АНТИТЕЛА

Also Published As

Publication number Publication date
US20120328608A1 (en) 2012-12-27
US9200071B2 (en) 2015-12-01
BR112012007252A2 (pt) 2020-08-11
IL218662A0 (en) 2012-05-31
JP2017014219A (ja) 2017-01-19
JP6025563B2 (ja) 2016-11-16
EP2483311A2 (fr) 2012-08-08
HK1170505A1 (en) 2013-03-01
JP2015145362A (ja) 2015-08-13
MX342250B (es) 2016-09-22
CN102630229A (zh) 2012-08-08
KR101782180B1 (ko) 2017-10-23
AU2010300747A1 (en) 2012-04-26
CN102630229B (zh) 2015-03-04
ZA201201984B (en) 2013-05-29
JP2013506675A (ja) 2013-02-28
PE20120998A1 (es) 2012-08-14
KR20120100952A (ko) 2012-09-12
CR20120213A (es) 2012-07-09
WO2011041336A3 (fr) 2012-05-03
EP2483311B1 (fr) 2016-05-18
ES2580229T3 (es) 2016-08-22
RU2012117619A (ru) 2013-11-10
CL2012000800A1 (es) 2012-08-31
MX2012003851A (es) 2012-05-08
CA2775880A1 (fr) 2011-04-07
WO2011041336A2 (fr) 2011-04-07
CO6531430A2 (es) 2012-09-28
ECSP12011858A (es) 2012-06-29

Similar Documents

Publication Publication Date Title
MA33973B1 (fr) Méthodes de traitement du cancer à l'aide d'antagonistes de notch
AU2022259847B2 (en) AXL-specific antibody-drug conjugates for cancer treatment
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
PH12016502066A1 (en) Methods of treating bladder cancer
EA201171367A1 (ru) Винилиндазолильные соединения
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
CR20120202A (es) Métodos y composiciones para tratar cáncer
IN2012DN02018A (fr)
MY156667A (en) Disubstituted phthalazine hedgehog pathway antagonists
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
MX2012010434A (es) Compuestos y composiciones novedosas para atacar a las celulas madre del cancer.
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
EA201270606A1 (ru) Новое противоопухолевое применение кабазитаксела
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
MX2022007678A (es) Compuestos y metodos para la degradacion dirigida del receptor de androgenos.
MX2013002155A (es) Compuestos para el tratamiento de cancer.
MX2009010271A (es) Tratamiento combinado del cancer con anticuerpo anti cd20 e interleucina 18 humana.
FR2945210B1 (fr) Combinaison antitumorale comprenant l'ave8062 et le sorafenib
MX2010008994A (es) Combinacion que comprende paclitaxel para el tratamiento del cancer de ovario.
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
ATE544455T1 (de) Zusammensetzungen und verfahren für die krebsbehandlung